Umeclidinium bromide/vilanterol
Umeclidinium bromide/vilanterol (trade name Anoro Ellipta) is a combination drug approved for the treatment of chronic obstructive pulmonary disease (COPD).[1][2] It is applied as an inhalation.
Umeclidinium bromide (TOP), vilanterol (BOTTOM) | |
Combination of | |
---|---|
Umeclidinium bromide | Muscarinic antagonist |
Vilanterol | Ultra-long-acting β2 agonist |
Clinical data | |
Trade names | Anoro Ellipta |
AHFS/Drugs.com | anoro-ellipta |
License data | |
Pregnancy category |
|
Routes of administration | Inhalation (DPI) |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
KEGG |
References
- Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
- "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
α1 |
|
---|---|
α2 |
|
β |
|
See also |
mAChRs |
| ||||
---|---|---|---|---|---|
Precursors (and prodrugs) | |||||
See also: Receptor/signaling modulators • Nicotinic acetylcholine receptor modulators • Acetylcholine metabolism/transport modulators |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.